TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17979577
Drug: Moderate to
Normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate to severe ADHD treatment
Study: 15494637
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2
Study: 11710635
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 i.v. bolus) followed 24 h later by paclitaxel (200 mg/m2 i.v. over 3 h)
Study: 11710635
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 i.v. bolus) followed 30 min later by paclitaxel (200 mg/m2 i.v. over 3 h)
Study: 8045206
Drug: First group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: First group intestinal preparation
Study: 8045206
Drug: Second group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second group intestinal preparation
Study: 8045206
Drug: Third group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third group intestinal preparation
Study: 27317414
Drug: Idarucizumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (1, 2.5 and 5 g or 2 × 2.5 g 1 h apart)
Study: 27317414
Drug: Idarucizumab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (doses ≥2.5 g)
Study: 24431895
Drug: LdT (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LdT (600 mg/d orally) + ADV (10 mg/d orally)
Study: 24431895
Drug: LAM (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM (100 mg/d orally) + ADV (10 mg/d orally)
Study: 18450930
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for late-life depression (structured conditions for up to 12 weeks)
Study: 14679117
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 (arm A)
Study: 14679117
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 (arm B)
Study: 9134632
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for up to six months (discontinued after the first event)
Study: 27986370
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ethyl chloride spray)
Study: 23881346
Drug: BIB® (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIB® (6 months) followed by diet therapy (7 months)
Study: 21976264
Drug: Client-oriented Occupational
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-oriented Occupational Therapy methods
Study: 9751013
Drug: Engerix B
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B (1 ml, 20 micrograms)
Study: 9751013
Drug: Hepavax (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepavax (1 ml, 20 micrograms)
Study: 9751013
Drug: Gen Hevac
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gen Hevac B (combined S and PreS subunit vaccine, 1 ml, 20 micrograms)
Study: 9751013
Drug: Standard isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard isolated S-antigen-containing vaccines (Engerix B or Hepavax)
Study: 3411179
Drug: Progesterone in
Normalized name: Progesterone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone in oil 25 mg intramuscularly daily from day +4 to day +18
Study: 25017114
Drug: Iced-slush ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iced-slush ingestion (SLUSH), 7 g·kg(‐1) body weight
Study: 8556970
Drug: Carbamazepine 400
Normalized name: carbamazepine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 400 mg daily
Study: 1977949
Drug: Aerosolized beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized beta 2‐agonists only
Study: 1977949
Drug: Combined aerosolized
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined aerosolized beta 2‐agonists with intravenous AMP
Study: 1977949
Drug: Intravenous AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous AMP
Study: 1977949
Drug: Aerosolized beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized beta 2‐agonists
Study: 343788
Drug: Metamizole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole (2.5 mg)
Study: 31370668
Drug: 3‐mL intra‐articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mL intra‐articular injection of atelocollagen (BioCollagen group)
Study: 23305083
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (20 mg rabeprazole and 1 g amoxicillin for the first week, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole for the second week)
Study: 23305083
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (20 mg rabeprazole, 1 g amoxicillin, 500 mg clarithromycin, and 500 mg metronidazole for 2 weeks)
Study: 19581544
Drug: Infants born
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants born to mothers shorter than 145 cm weighing 3300 g
Study: 9156377
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (500 mg every 12 hours)
Study: 3534201
Drug: Thiopental treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental treatment
Study: 23286558
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy (MCT), 11 to 13 sessions
Study: 22100355
Drug: Multidisciplinary cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary cognitive behavioral treatment program
Study: 2148632
Drug: MPA treatment
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA treatment with mild exercise
Study: 2148632
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with mild exercise
Study: 2148632
Drug: MPA treatment
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA treatment
Study: 31834099
Drug: LOW (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW (150 mg·kg body mass tyrosine)
Study: 31834099
Drug: MED (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED (300 mg·kg body mass tyrosine)
Study: 31834099
Drug: HIGH (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (400 mg·kg body mass tyrosine)
Study: 31834099
Drug: PLA (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (0 mg tyrosine)
Study: 28746178
Drug: High CMV
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CMV viral load (>2.52 log copies/mL)
Study: 28746178
Drug: Low CMV
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low CMV viral load (≤2.52 log copies/mL)
Study: 23139359
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d atorvastatin
Study: 16154544
Drug: D-alanine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-alanine (100 mg/kg/day)
Study: 14633532
Drug: Triple preincisional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple preincisional analgesic therapy (rofecoxib 50 mg PO, 0.25% bupivacaine/0.5% lidocaine field block, ketamine 0.2 mg/kg IV)
Study: 1347763
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg xamoterol twice daily
Study: 1347763
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg xamoterol twice daily
Study: 1347763
Drug: Xamoterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (100 mg and 200 mg)
Study: 3896701
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen administration
Study: 30208475
Drug: aP vaccine
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aP vaccine plus HBV (n = 221)
Study: 22370444
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g WBE/d
Study: 22370444
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g WBE/d
Study: 22370444
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g WBE/d (placebo)
Study: 18540008
Drug: Transfers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfers of only embryos from rHuPH20 treatment
Study: 18540008
Drug: Transfers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfers of only embryos from bovine hyaluronidase treatment
Study: 15935238
Drug: Continuing mood
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing mood stabilizer therapy
Study: 8740607
Drug: Amitriptyline (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (dose escalated from 25 mg to 100 mg per day over 4 weeks)
Study: 7046784
Drug: Co-trimoxazole by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole by intramuscular injection immediately before operation
Study: 31177635
Drug: Theatre Improvisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theatre Improvisation Training to Promote Social Cognition (TIPS) - 18 weekly 2-hour group sessions led by a theatre director and actor-assistant.
Study: 25050468
Drug: CMV pp65
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC) administered intradermally at a weekly interval for 4 weeks
Study: 19236376
Drug: Sequential deferiprone-deferoxamine
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential deferiprone-deferoxamine (DFO-DFP)
Study: 17599426
Drug: Simvastatin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (titrated to 40 mg/day if necessary) plus placebo
Study: 17599426
Drug: Simvastatin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (titrated to 40 mg/day if necessary) plus active fenofibrate 160 mg/day (or 54 mg/day if eGFR 30 to <50 mL/min per 1.73 m2)
Study: 15533894
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate supplementation (25,000, 50,000, or 75,000 IU daily)
Study: 9802965
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg nebulized glyceryl trinitrate (GTN)
Study: 2681580
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline (IURT)
Study: 30742386
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of magnetolaser therapy (MLT) and red light (10 procedures per course)
Study: 30742386
Drug: Basic therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapeutic complex (medicamentous therapy, prostate massage, diet therapy, therapeutic gymnastics)
Study: 26279411
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (GTN) 0.4 mg/h
Study: 24912462
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR, 12 sessions
Study: 24912462
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR
Study: 24912462
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (European Americans receiving combined treatment)
Study: 9140633
Drug: New atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New atypical antipsychotic
Study: 3300133
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg orally 1 hour before abortion and again 4 and 8 hours after
Study: 31627728
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.4% ropivacaine (Group T)
Study: 28902593
Drug: PFO closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFO closure plus long-term antiplatelet therapy
Study: 28902593
Drug: PFO closure,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFO closure, oral anticoagulation, and antiplatelet therapy
Study: 25395283
Drug: Figitumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (20 mg/kg) plus erlotinib (150 mg/day)
Study: 15004870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no management or treatment)
Study: 11520714
Drug: Terbutaline inhalation
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhalation via a pressurized metered-dose inhaler
Study: 11520714
Drug: Terbutaline inhalation
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhalation
Study: 11520714
Drug: sRaw bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sRaw bronchodilator response
Study: 9764456
Drug: Ticlopidine, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine, 250 mg b.d. for 7 days before surgery and continued for 28 days after surgery
Study: 8154176
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ASA daily
Study: 8154176
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ASA daily
Study: 31701133
Drug: Methylphenidate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.25 mg/kg)
Study: 31694699
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy-based program designed to enhance resilience, focusing on emotion regulation through cognitive reappraisal, delivered in four bi-weekly 120-min sessions.
Study: 31694699
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy-based program.
Study: 26354104
Drug: Hyoid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoid suspension type 2 (HS) + radiofrequency treatment of the base of the tongue (RFT TB)
Study: 19781209
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg b.i.d for 3 days before and after intervention
Study: 19781209
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no probucol treatment)
Study: 19781209
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg b.i.d
Study: 14513873
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisolone/day
Study: 11751733
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg once daily)
Study: 8516658
Drug: Cisapride 30
Normalized name: cisapride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 30 mg/day
Study: 8516658
Drug: Metoclopramide 30
Normalized name: metoclopramide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 30 mg/day
Study: 8516658
Drug: Domperidone 30
Normalized name: domperidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 30 mg/day
Study: 27880789
Drug: Rumination-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumination-Focused Cognitive Behavior Therapy (RFCBT) for 8 weeks
Study: 25097754
Drug: SUB‐B (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUB‐B (10,000 AUN/ml)
Study: 25097754
Drug: Stal‐B (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stal‐B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml)
Study: 19955506
Drug: Aminophylline 6
Normalized name: aminophylline 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 6 mg/kg IV, followed by 1.5 mg x kg(‐1) x h(‐1)
Study: 10442940
Drug: Particulate dentin
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Particulate dentin and plaster of paris combination
Study: 2151369
Drug: Cyclical use
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate (TAM/HD‐MPA)
Study: 883328
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (wide local excision and radical mastectomy)
Study: 10411194
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered trivalent LAIV vaccine
Study: 7574055
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (preoperative bolus of bupivacaine followed by an infusion of bupivacaine)
Study: 7574055
Drug: Group MB
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MB (preoperative bolus of epidural bupivacaine and morphine followed by an infusion of morphine and bupivacaine)
Study: 7574055
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (preoperative bolus of epidural morphine followed by an infusion of morphine)
Study: 7574055
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (preoperative bolus of intravenous morphine followed by intravenous patient‐controlled morphine postoperatively)
Study: 1309127
Drug: Assisted hatching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted hatching by zona drilling using acidic Tyrode's solution on embryos with thick zonae (> 15 microns).
Study: 1309127
Drug: Assisted hatching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted hatching by zona drilling using acidic Tyrode's solution on embryos with thin zonae (< 13 microns).
Study: 6532286
Drug: 1% indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% indomethacin ophthalmic solution
Study: 25107318
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy‐Primary Care (PST‐PC)
Study: 21392377
Drug: Five years
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five years of OPUS treatment
Study: 21392377
Drug: Two years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two years of OPUS treatment
Study: 11248153
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy plus trastuzumab
Study: 9579879
Drug: rhEPO (5x500
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (5x500 U/kg body weight) + oral Fe2+ (300 mg/day)
Study: 9579879
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + oral Fe2+ (300 mg/day)
Study: 7538400
Drug: Prolase II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolase II fiber (cytocare) treatment for BPH
Study: 6797732
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) ointment, 7.5 mg
Study: 6797732
Drug: Propranolol (P),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (P), 20-40 mg, 3 times daily
Study: 6797732
Drug: Nifedipine (N),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (N), 10 mg, 3-4 times daily
Study: 31870556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pimasertib (60 mg daily) + SAR245409 (70 mg daily)
Study: 31870556
Drug: Pimasertib alone
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib alone (60 mg BID)
Study: 31870556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pimasertib + SAR245409
Study: 21298288
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese herbal medicine (Kangliuzengxiao decoction during chemotherapy and Feiyanning decoction after chemotherapy)
Study: 15514373
Drug: LV5FU2 (Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 (Leucovorin 200 mg/m2 + Fluorouracil 400 mg/m2 bolus + Fluorouracil 600 mg/m2 continuous infusion)
Study: 15514373
Drug: LV5FU2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 plus cisplatin (50 mg/m2)
Study: 15514373
Drug: LV5FU2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 plus irinotecan (180 mg/m2)
Study: 11694773
Drug: Concurrent schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent schedule of short-infusion IFO at total dose of 7.5-9 g/m² over 5 days plus iv bolus EPI at 90-120 mg/m²/cycle, repeated every 3 weeks (group A)
Study: 11694773
Drug: Sequential schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential schedule of dose-intense, continuous infusion IFO at a total dose of 14-18 g/m² for 2 cycles followed by bimonthly EPI at 120-160 mg/m²/cycle (group B)
Study: 762958
Drug: High potassium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High potassium cardioplegic solution (20 mEq. per liter)
Study: 762958
Drug: Low potassium
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low potassium cardioplegic solution (5 mEq. per liter)
Study: 31118371
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg repaglinide per day (1 mg each time before meals) for 8 weeks